Alpha-blockers have been established as medical expulsive therapy for urolithiasis. We aimed to assess the effect of tamsulosin and doxazosin as adjunctive therapy following SWL for renal calculi. We prospectively included 150 patients who underwent up to four SWL sessions for renal stones from June 2008 to 2009. Patients were randomized into three groups of 50 patients each, group A (phloroglucinol 240 mg daily), group B (tamsulosin 0.4 mg once daily plus phloroglucinol), and group C (doxazosin 4 mg plus phloroglucinol). The treatment continued up to maximum 12 weeks. Patients were evaluated for stone expulsion, colic attacks, amount of analgesics and side-effects of alpha-blockers. There were no significant differences between the groups regarding stone expulsion rates (84; 92 and 90%, respectively). The mean expulsion time of tamsulosin was significantly shorter than both control group (p = 0.002) and doxazosin (p = 0.026). Both number of colic episodes and analgesic dosage were significantly lower with tamsulosin as compared to control and doxazosin. Steinstrasse was encountered in 10 (6.7%) patients with no significant difference between the groups. 16 patients on tamsulosin and 21 on doxazosin experienced adverse effects related to postural hypotension. Moreover, 2 (4%) patients in the tamsulosin group reported ejaculatory complaints. In conclusion, adjunction of tamsulosin or doxazosin after SWL for renal calculi decreases the time for stone expulsion, amount of the analgesics and number colic episodes. There was no benefit regarding the overall stone expulsion rate. The side-effects of these agents are common and should be weighted against the benefits of their usage.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00240-011-0410-xDOI Listing

Publication Analysis

Top Keywords

tamsulosin doxazosin
16
stone expulsion
16
renal calculi
12
tamsulosin
8
doxazosin adjunctive
8
adjunctive therapy
8
swl renal
8
groups patients
8
amount analgesics
8
number colic
8

Similar Publications

Association between alpha blocker use and the risk of fractures in patients with chronic kidney disease: a cohort study.

BMC Nephrol

December 2024

Department of Nephrology, Graduate School of Medicine, Nagoya University, Tsurumai-Cho 65, Showa-Ku, Nagoya City, Aichi Prefecture, Japan.

Article Synopsis
  • Alpha blockers (ABs) are commonly given to patients with chronic kidney disease (CKD) who often deal with high blood pressure, but the link between ABs and fracture risk is unclear, prompting this study.
  • The research analyzed a large cohort from a Japanese medical database, focusing on patients newly prescribed either ABs for hypertension or non-AB antihypertensive medications, with separate analyses for males and females.
  • The findings showed that while males had no increased fracture risk with AB use, females using ABs for voiding dysfunction exhibited a significant rise in fracture risk compared to those on antihypertensive ABs.
View Article and Find Full Text PDF
Article Synopsis
  • Alpha-1 adrenergic receptor (α1-AR) antagonists are drugs often used to treat benign prostatic hyperplasia and hypertension, but their potential link to cognitive impairment remains debated.
  • A systematic review was conducted to evaluate the association between these medications and cognitive dysfunction, analyzing 7 studies, primarily focusing on tamsulosin.
  • The findings suggested no strong causal relationship between α1-AR antagonists and cognitive issues, indicating these medications can be used without significant concern for affecting cognition.
View Article and Find Full Text PDF

Background: Urinary incontinence (UI) is a common medical problem that seriously affects patients' physical, psychological, social, and financial well-being. To identify the most effective drug management techniques, this retrospective study aimed to describe the demographics, etiology, and medical traits of people with UI.

Methods: This retrospective study was conducted at Rumailah Hospital, Ambulatory Care Centre, and Hamad General Hospital to investigate UI risk factors, causes, and management practices in people aged ≥ 65 years within the Hamad Medical Corporation (HMC) in Qatar.

View Article and Find Full Text PDF

Purpose: To study the effects of benign prostatic hyperplasia treatments, namely: alpha-adrenergic receptor blockers, 5-alpha-reductase inhibitors and phosphodiesterase-5 inhibitors on the risk of Parkinson's disease, Alzheimer's disease and mortality.

Materials And Methods: All male Medicare enrollees aged 65 or above who were diagnosed with benign prostatic hyperplasia and received one of the study drugs between 2007-2020 were followed-up for the three outcomes. We used Cox regression analysis to assess the relative risk of each of the outcomes for each study drug compared to the most prescribed drug, tamsulosin, while controlling for demographic, socioeconomic and comorbidity factors.

View Article and Find Full Text PDF

Benign prostatic hyperplasia is one of the most common diseases in men, with a prevalence rate of 50% in their 50s to 80% in their 80s, and is mostly treated with chronic drug therapy. The aim of this study was to analyze adverse drug reactions (ADR) to drugs used in benign prostate hyperplasia (BPH) treatment reported to HALMED from 2008 to 2021. Data on ADR reports in Croatia were obtained from the VigiFlow national database and on the use of drugs for BPH in Croatia from Drug Utilization Reports from HALMED.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!